Application No.: 10/821,584 Docket No.: 381092000623

## CLAIM AMENDMENTS

 (currently amended): A method to treat a condition selected from the group consisting of pain, stroke, epilepsy, anxiety and depression in a subject, which method comprises administering to a subject in need of such treatment an amount of a compound of formula (1) effective to treat said condition wherein said compound of formula (1) is:

$$\begin{array}{c|c}
R^{1}_{n1} \\
A \\
A
\end{array}$$

$$\begin{array}{c|c}
R^{3}_{n3} \\
C
\end{array}$$

$$\begin{array}{c|c}
C$$

$$\begin{array}{c|c}
C
\end{array}$$

$$\begin{array}{c|c}
C$$

$$C$$

or a pharmaceutically acceptable salt thereof

wherein each  $R^1$ - $R^5$  is independently optionally substituted alkyl (1-10C), alkenyl (2-10C), alkylaryl (7-16C) or alkenylaryl (7-16C) each optionally further containing 1-4 heteroatoms (N, O or S) and wherein said optional substituents may include =O; or each of  $R^1$ - $R^5$  is independently halo, NO<sub>2</sub>, SO, SO<sub>2</sub>, SO<sub>2</sub>NH<sub>2</sub>, -OH, SH or NH<sub>2</sub>, and wherein  $R^3$  may be keto if  $n^3$  = 1; and

wherein two substituents on adjacent positions of the same ring may form a 3-7 membered saturated or unsaturated ring fused to said substituted ring, said fused ring itself optionally substituted and optionally containing one or more heteroatoms (N, S, O); or

wherein a combination of R<sup>1</sup> and R<sup>2</sup> and/or R<sup>4</sup> and R<sup>5</sup> may form a bond or a bridge between phenyl groups A and B and/or C and D; and

wherein each  $+^4 - n^2$  and  $n^4 - n^5 - \frac{1}{n^2}$ ,  $\frac{n^3}{n^3}$ ,  $\frac{n^4}{n^4}$  and  $\frac{n^5}{n^5}$  is independently 0-4, and  $\frac{n^3}{n^5}$  is 1-4; and/or the compound of formula (1) is in the form of an isolated stereoisomer; or the compound of formula (1) is P49 or P50 in Figure (1) or a salt thereof.

sd-455606 2

Application No.: 10/821,584 Docket No.: 381092000623

(original): The method of claim 1 wherein each of R1. R2. R4 and R5 is 2. independently halo, or is optionally heteroatom containing and/or optionally substituted alkyl. alkenyl, aryl, arylalkyl, arylalkenyl, or phenoxy.

- (withdrawn): The method of claim 1 wherein R<sup>1</sup> and R<sup>2</sup> and/or R<sup>4</sup> and R<sup>5</sup> form a 3. bridge of 1-3 members.
- (withdrawn): The method of claim 1 wherein n<sup>3</sup> is 1 and R<sup>3</sup> is COOH or an alkyl 4. ester thereof.
  - (withdrawn): The method of claim 1 wherein all of n<sup>1</sup>-n<sup>2</sup> and n<sup>4</sup>-n<sup>5</sup> are 0. 5.
- (previously presented): The method of claim 1 wherein one of n<sup>1</sup>-n<sup>2</sup> and n<sup>4</sup>-n<sup>5</sup> is 1 6. and the other n are 0.
- (withdrawn): The method of claim 1 wherein one of n<sup>1</sup>-n<sup>2</sup> and n<sup>4</sup>-n<sup>5</sup> is 2 and the 7. other n are 0.
- (withdrawn): The method of claim 1 wherein one of n<sup>1</sup>-n<sup>2</sup> and n<sup>4</sup>-n<sup>5</sup> is 3 and the 8. other n are 0
- 9. (withdrawn): The method of claim 1 which is compound P37-P50 in Figure 1 or a salt thereof.
  - 10. (original): The method of claim 1 wherein the condition is pain.
  - 11. (withdrawn): The method of claim 1 wherein the condition is stroke.
  - 12. (withdrawn): The method of claim 1 wherein the condition is epilepsy.
- (withdrawn): The method of claim 1 wherein the condition is anxiety or depression. 13. 3

sd-455606

Application No.: 10/821,584 Docket No.: 381092000623

14. (withdrawn): The method of claim 5 wherein the condition is pain.

15. (withdrawn): The method of claim 5 wherein the condition is stroke.

16. (withdrawn): The method of claim 5 wherein the condition is epilepsy.

17. (withdrawn): The method of claim 5 wherein the condition is anxiety or depression.

sd-455606 4